Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study-Reference-Cited by-同舟云学术

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study

Published:2019-12-09 Issue:2 Volume:18 Page:479-484
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Knoebl Paul¹,Cataland Spero²^ORCID,Peyvandi Flora³⁴^ORCID,Coppo Paul⁵,Scully Marie⁶,Kremer Hovinga Johanna A.⁷^ORCID,Metjian Ara⁸,Rubia Javier⁹¹⁰,Pavenski Katerina¹¹,Minkue Mi Edou Jessica¹²,De Winter Hilde¹³,Callewaert Filip¹⁴

Affiliation:

1. Division of Hematology and Hemostasis Department of Medicine 1 Medical University of Vienna Wien Austria

2. Division of Hematology Department of Internal Medicine The Ohio State University Columbus OH USA

3. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy

4. Department of Pathophysiology and Transplantation Università degli Studi di Milano Milan Italy

5. Department of Hematology Reference Center for Thrombotic Microangiopathies (CNR‐MAT) Saint‐Antoine University Hospital AP‐HP Paris France

6. Cardiometabolic Programme‐NIHR UCLH/UCL BRC Department of Haematology University College London Hospital London UK

7. Department of Hematology and Central Hematology Laboratory, Inselspital Bern University Hospital University of Bern Bern Switzerland

8. Department of Medicine Duke University School of Medicine Durham NC USA

9. Hematology Department, Internal Medicine School of Medicine and Dentistry Catholic University of Valencia Valencia Spain

10. Hospital Doctor Peset Valencia Spain

11. Departments of Medicine and Laboratory Medicine St. Michael's Hospital University of Toronto Toronto ON Canada

12. Clinical Development Ablynx, a Sanofi Company Ghent Belgium

13. Formerly Clinical Development Ablynx, a Sanofi Company Ghent Belgium

14. Medical Affairs Sanofi Diegem Belgium

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14679

Reference22 articles.

1. Thrombotic thrombocytopenic purpura

2. What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura

3. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

4. Pathophysiology of thrombotic thrombocytopenic purpura

5. THROMBOTIC THROMBOCYTOPENIC PURPURA

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tailoring caplacizumab administration using ADAMTS13 activity for immune-mediated thrombotic thrombocytopenic purpura;Blood Vessels, Thrombosis & Hemostasis;2024-09

2. Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments — an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES);Emergencias;2024-07-02

3. Ausgewählte hämato-onkologische Notfälle;Notaufnahme up2date;2024-04

4. 100 Years of Thrombotic Thrombocytopenic Purpura: A Story of Death and Life;Hämostaseologie;2024-02

5. A SYSTEMATIC REVIEW ON CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA;Asian Journal of Pharmaceutical and Clinical Research;2023-12-07